Placebo Control

SEPTEMBER 25, 2013

Although a few articles on this site are older, I really only began blogging in earnest about 15 months ago. However, I suppose that's long enough that I can count myself as at least somewhat established, and take a moment to welcome and encourage some interesting newcomers to the scene. Bloggers in dank basements their natural habitat. There are 3 relative newcomers that I've found really interesting, all with very different perspectives on drug development and clinical research: Pharmagellan T

Development 40

Development Drugs Clinical Trials Clinical Trials 40

Placebo Control

SEPTEMBER 19, 2013

The authors of the study I blogged about on Monday were kind enough to post a lengthy comment, responding in part to some of the issues I raised. I thought their response was interesting, and so reprint it in its entirety below, interjecting my own reactions as well. There were a number of points you made in your blog and the title of questionable maths was what caught our eye and so we reply on facts and provide context.

Trials 40

Trials Clinical Trials Clinical Trials Scientist 40

Placebo Control

SEPTEMBER 16, 2013

There has been considerable noise coming out of the UK lately about successes in clinical trial enrollment. First, a couple months ago came the rather dramatic announcement that clinical trial participation in the UK had " tripled over the last 6 years ". That announcement, by the chief executive of the Sweet creature of bombast: is Sir John writing press releases for the NIHR?

Clinical Trials 40

Clinical Trials Clinical Trials Trials Research 40

Placebo Control

SEPTEMBER 3, 2013

“Children are not small adults.” We invoke this saying, in a vague and hand-wavy manner, whenever we talk about the need to study drugs in pediatric populations. It’s an interesting idea, but it really cries out for further elaboration. If they’re not small adults, what are they? Are pediatric efficacy and safety totally uncorrelated with adult efficacy and safety?

Drugs 40

Drugs Medicine Compliance Trials 40

Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

Clinical Trials